









Markets
/
Stocks
/
nasdaq-mrvi
/

Maravai LifeSciences Holdings Inc

MRVI

2.870USD

-0.020-0.69%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

415.05MMarket Cap

LossP/E TTM



Maravai LifeSciences Holdings Inc

2.870

-0.020-0.69%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Maravai LifeSciences Holdings Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Maravai LifeSciences Holdings Inc's Score

Industry at a Glance

Industry Ranking

103 / 407

Overall Ranking

226 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

3.857

Target Price

+34.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Maravai LifeSciences Holdings Inc Highlights

StrengthsRisks

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Fairly Valued

The company’s latest PE is -3.41, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 128.59M shares, decreasing 25.67% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 13.82K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 6.81, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 47.40M, representing a year-over-year decrease of 35.43%, while its net profit experienced a year-over-year decrease of 421.96%.

Score

Industry at a Glance

Previous score

6.81

Change



Financials

8.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.32

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.54

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.14

Key Metrics

Free cash flow

No Data

Maravai LifeSciences Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.48, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.41, which is -1649.57% below the recent high of 52.87 and -234.68% above the recent low of -11.42.

Score

Industry at a Glance

Previous score

7.48

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 103/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.27, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Maravai LifeSciences Holdings Inc is 4.00, with a high of 5.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.27

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

3.857

Target Price

+34.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Maravai LifeSciences Holdings Inc

MRVI

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.17, which is lower than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 3.50 and the support level at 2.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.83

Change

0.34

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.149

Neutral

RSI(14)

40.364

Neutral

STOCH(KDJ)(9,3,3)

27.399

Buy

ATR(14)

0.201

Low Volatility

CCI(14)

-122.033

Sell

Williams %R

69.767

Sell

TRIX(12,20)

-0.106

Sell

StochRSI(14)

12.698

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

2.888

Sell

MA10

3.036

Sell

MA20

3.212

Sell

MA50

2.966

Sell

MA100

2.710

Buy

MA200

2.734

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 88.88%, representing a quarter-over-quarter decrease of 11.31%. The largest institutional shareholder is The Vanguard, holding a total of 7.13M shares, representing 4.93% of shares outstanding, with 40.79% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

GTCR Golder Rauner, LLC

20.15M

12 West Capital Management, L.P.

12.52M

BlackRock Institutional Trust Company, N.A.

8.41M

+0.63%

Braidwell LP

8.35M

The Vanguard Group, Inc.

Star Investors

9.38M

-19.38%

Hudson View Capital LLC

6.87M

Mackenzie Investments

6.07M

-0.72%

Renaissance Technologies LLC

Star Investors

4.19M

+1.84%

Mirabella Financial Services LLP

3.75M

+0.27%

Point72 (DIFC) Ltd

3.72M

+138.99%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.52, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.